Delayed Triple Intrathecal Therapy in ALL May Be Beneficial
the Cancer Therapy Advisor take:
In children with acute lymphoblastic leukemia, delaying first first triple intrathecal therapy (TIT) until disappearance of peripheral blood blasts may be beneficial, according to one study. Researchers evaluated the administration of TIT without cranial irradiation (CrRT) in 152 children with newly diagnosed ALL at disappearance of blasts or up until 10 days of multidrug induction. Results showed four patients experienced traumatic lumbar punctures, although none had lymphoblast contamination. Five-year event free and overall survival rates were 84.2% and 90.6%, respectively. Isolated CNS relapse did not occur in any patients, but combined relapse occurred in two patients. Cumulative risk for CNS relapse was 1.7% at 7 years, according to the data. These results suggest that delaying first TIT until peripheral blood blasts disappear may improve CNS control and eliminate the need for CrRT, thereby preventing the toxicities and risks associated with the treatment, in this patient population, the researchers wrote.

Delayed Triple Intrathecal Therapy in ALL May Be Beneficial
The purpose of this study was to eliminate the toxicities and sequelae of cranial irradiation (CrRT) and to minimize the adverse impact of traumatic lumbar puncture (TLP) with blasts in children with acute lymphoblastic leukemia (ALL). Since June 1999, children with newly diagnosed ALL have been treated with triple intrathecal therapy (TIT) alone without CrRT.
Related Resources
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Opinion: Understanding the FDA's Take on Cannabidiol
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer